Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sangamo Therapeutics (NQ: SGMO )

0.5400 -0.0151 (-2.72%)
Streaming Delayed Price Updated: 10:06 AM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sangamo Therapeutics

< Previous 1 2 Next >
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
From Sangamo Therapeutics, Inc.
Via Business Wire
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
From Sangamo Therapeutics, Inc.
Via Business Wire
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients
From Sangamo Therapeutics, Inc.
Via Business Wire
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
From Sangamo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.